Amanote Research
Register
Sign In
Assessing the Benefit–risk of New Treatments Using Generalised Pairwise Comparisons: The Case of Erlotinib in Pancreatic Cancer
British Journal of Cancer
- United Kingdom
doi 10.1038/bjc.2015.55
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
February 17, 2015
Authors
J Péron
P Roy
K Ding
W R Parulekar
L Roche
M Buyse
Publisher
Springer Science and Business Media LLC
Related search
The Promise of Risk-Based Allocation Trials in Assessing New Treatments.
American Journal of Public Health
Environmental
Public Health
Occupational Health
Supplemental Information 2: Differentially Expressed Transcripts From Pairwise Comparisons of Tissues or Temperature Treatments.
Notes on the Existence of a Solution in the Pairwise Comparisons Method Using the Heuristic Rating Estimation Approach
Annals of Mathematics and Artificial Intelligence
Applied Mathematics
Artificial Intelligence
Application of the Method of Pairwise Comparisons When Combining Economic Forecasts
Accounting. Analysis. Auditing
Potentiation of the Effect of Erlotinib by Genistein in Pancreatic Cancer: The Role of Akt and Nuclear Factor- B
Cancer Research
Cancer Research
Oncology
Automated Pancreatic Cyst Screening Using Natural Language Processing: A New Tool in the Early Detection of Pancreatic Cancer
HPB
Hepatology
Gastroenterology
Graded Multilabel Classification by Pairwise Comparisons
The Role of Mediterranean Diet on the Risk of Pancreatic Cancer
British Journal of Cancer
Cancer Research
Oncology
Assessing Employment Risk: New Dimensions in the Measurement of Unemployment.
Socialist Studies/Études Socialistes
